ArticleScientific reports2024
Semi-supervised recognition for artificial intelligence assisted pathology image diagnosis.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- AI Quantification of Vascular Lesions in Mouse Fundus Fluorescein Angiography.Translational vision science & technology · 2025Article
- Artificial Intelligence-Powered Quality Assurance: Transforming Diagnostics, Surgery, and Patient Care-Innovations, Limitations, and Future Directions.Life (Basel, Switzerland) · 2025Review
- A weakly supervised deep learning framework for automated PD-L1 expression analysis in lung cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The analysis and interpretation of cytopathological images are crucial in modern medical diagnostics. However, manually locating and identifying relevant cells from the vast amount of image data can be a daunting task. This challenge is particularly pronounced in developing countries where there may be a shortage of medical expertise to handle such tasks. The challenge of acquiring large amounts of high-quality labelled data remains, many researchers have begun to use semi-supervised learning methods to learn from unlabeled data. Although current semi-supervised learning models partially solve the issue of limited labelled data, they are inefficient in exploiting unlabeled samples. To address this, we introduce a new AI-assisted semi-supervised scheme, the Reliable-Unlabeled Semi-Supervised Segmentation (RU3S) model. This model integrates the ResUNet-SE-ASPP-Attention (RSAA) model, which includes the Squeeze-and-Excitation (SE) network, Atrous Spatial Pyramid Pooling (ASPP) structure, Attention module, and ResUNet architecture. Our model leverages unlabeled data effectively, improving accuracy significantly. A novel confidence filtering strategy is introduced to make better use of unlabeled samples, addressing the scarcity of labelled data. Experimental results show a 2.0% improvement in mIoU accuracy over the current state-of-the-art semi-supervised segmentation model ST, demonstrating our approach's effectiveness in solving this medical problem.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.